Tag: advisory

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

NEW YORK und MAINZ, Deutschland, 25. Juli 2025 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an LP.8.1 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY^® LP.8.1) der Unternehmen für die aktive Immunisierung zur Vorbeugung von COVID-19 verursacht durch SARS-CoV-2 bei Personen ab 6 Monaten ausgesprochen hat. Die Anpassung basiert auf der Empfehlung der Notfall-Taskforce (Emergency Task Force, „ETF“) der EMA, die vorschlägt, COVID-19-Impfstoffe zu aktualisieren, um die LP.8.1-Variante für die Impfkampagne 2025-2026 abzudecken. Die Notfall-Taskforce erklärte: „Eine Anpassung an LP.8.1 wird dabei helfen, die Wirksamkeit der Impfstoffe gegen das sich fortlaufend weiterentwickelnde SARS-CoV-2 aufrechtzuerhalten.“² 

CALGARY, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to report its second quarter results marked by strong operational performance, consistent financial results and execution on return of capital commitments. With low corporate break-evens, differentiated long-life assets and a pristine balance sheet, the Company is well positioned to advance its strategic priorities.

ST. JOHN'S, Newfoundland and Labrador, July 24, 2025 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its second quarter 2025 financial results on Friday, August 1, 2025. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's second quarter financial results.

New ‘Big Beautiful Bill’ Creates a 2026 ‘Certainty Cliff’ Due to Supply Chain Rules, Interconnection Delays, and Shifting ITC Requirements, Prompting CFOs and VPs of Finance to Accelerate Project Planning.

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) --

AGF Investments Inc. (AGF Investments) today announced the July 2025 cash distributions for AGF Enhanced U.S. Equity Income Fund*, AGF Total Return Bond Fund* and AGF Systematic Global Infrastructure ETF, which pay monthly distributions. Unitholders of record on July 31, 2025 will receive cash distributions payable on August 7, 2025.

Details regarding the final “per unit” distribution amounts are as follows:

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the second quarter ended June 30, 2025 and updated its full year 2025 Outlook, as reflected in the table below.